New developments in the era of viral hepatitis vaccines

Abstract

Chronic hepatitis B and hepatitis C infections are major healthproblems in the world. Therefore, prevention of the transmission ofthe viral infections gets higher priority. Development of hepatitisB vaccines by recombinant technology provide higher preventionrates. However, this success could not be achieved with hepatitisC vaccine. The present review discusses recent developments forhepatitis B and C vaccines.Keywords: New vaccines, Hepatitis B, Hepatitis C

References

1. McMahon BJ. Epidemiology and natural history of hepatitis
2. B. Semin Liver Dis 2005; 25 Suppl 1:3.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden
4. treatment, and current and emerging prevention and control
5. measures. J Viral Hepat 2004; 11:97.
6. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B
7. vaccine: demonstration of efficacy in a controlled clinical trial
8. in a high-risk population in the United States. N Eng J Med

9. 303:833–4.
10. McAleer WJ, Buynack EB, Maigetter RZ, Wampler DE
11. Miller WJ, Hilleman MR. Human hepatitis B vaccine from
12. recombinant yeast. Nature 1984;307:178–80.
13. Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson
14. B, Maddrey WC, US Hepacare Study Group, Adult hepatitis
15. B vaccination using a novel triple antigen recombinant
16. vaccine. Hepatology 2001;34:372.
17. Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibodyresponse
18. to three recombinant hepatitis B vaccines
19. comparative evaluation of multicenter travel-clinic based
20. experience. Vaccine 2001; 19:2055-60.
21. Blatter M, Joines R, Resinger K, et al. An open, randomized
22. controlled study to evaluate the safety and immunogenicity
23. of SmithKline Beecham Biologicals’ combined hepatitis A/
24. hepatitis B (Twinrix®) vaccine in adults (abstract 1629). In
25. Program and abstracts of the 39th Interscience Conference
26. on Antimicrobial Agents and Chemotherapy (San Francisco)
27. American Society for Microbiology, Washington, DC
28. 394.
29. Abraham B, Parenti D. Antibody production in response
30. to hepatitis B surface antigen in a combination hepatitis A/
31. hepatitis B vaccine. J Infect Dis 2000; 182:1005-6.
32. Hadler SC, Francis DP, Maynard JE, et al. Long-term
33. immunogenicity and efficacy of hepatitis B vaccine in
34. homosexual men. N Engl J Med 1986; 315:209-14.
35. Poland GA. Hepatitis B immunization in health care workers.
36. Dealing with vaccine nonresponse. Am J Prev Med 1998
37. 73-7.
38. Propst T, Propst A, Lhotta K, et al. Reinforced intradermal
39. hepatitis B vaccination in hemodialysis patients is superior
40. in antibody response to intramuscular or subcutaneous
41. vaccination. Am J Kidney Dis 1998; 32:1041-5.
42. Peces R, de la Torre M, Alcázar R, Urra JM. Prospective
43. analysis of the factors influencing the antibody response to
44. hepatitis B vaccine in hemodialysis patients. Am J Kidney
45. Dis 1997; 29:239-45.
46. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic
47. prediction of nonresponse to hepatitis B vaccine. N Engl J
48. Med 1989; 321:708-12.
49. Makidon PE, Bielinska AU, Nigavekar SS, et al. Preclinical
50. evaluation of a novel nanoemulsion-based hepatitis
51. B mucosal vaccine. PLoS One 2008; 3:e2954. doi: 10.1371/
52. journal.pone.0002954
53. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and
54. immunogenicity of two doses of investigational hepatitis B virus
55. surface antigen co-administered with an immunostimulatory
56. phosphorothioate oligodeoxyribonucleotide and three doses
57. of a licensed hepatitis B vaccine in healthy adults 18-55
58. years of age. Vaccine 2012; 30:2556-63. doi: 10.1016/j.
59. vaccine.2012.01.087
60. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of
61. safety and enhanced seroprotection against hepatitis B with
62. investigational HBsAg-1018 ISS vaccine compared to a
63. licensed hepatitis B vaccine. Vaccine 2012;30:2689-96. doi
64. 1016/j.vaccine.2012.02.001
65. Singh M, Li XM, McGee JP, et al. Controlled release
66. microparticles as a single dose hepatitis B vaccine: evaluation
67. of immunogenicity in mice. Vaccine 1997; 15:475-81.
68. Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular
69. and humoral immune responses induced by intradermal or
70. intramuscular vaccination with the major hepatitis B surface
71. antigen. Hepatology 2000; 31:521-7.
72. Rault R, Freed B, Nespor S, Bender F. Efficacy of different
73. hepatitis B vaccination strategies in patients receiving
74. hemodialysis. ASAIO J 1995; 41:M717.
75. Fabrizi F, Dixit V, Magnini M, et al. Meta-analysis
76. intradermal vs. intramuscular vaccination against hepatitis
77. B virus in patients with chronic kidney disease. Aliment
78. Pharmacol Ther 2006; 24:497-506.
79. Quiroga JA, Carreño V. Interferon and hepatitis B vaccine in
80. haemodialysis patients. Lancet 1989; 1:1264.
81. Jungers P, Devillier P, Salomon H, et al. Randomised
82. placebo-controlled trial of recombinant interleukin-2 in
83. chronic uraemic patients who are non-responders to hepatitis
84. B vaccine. Lancet 1994; 344:856.
85. Thoelen S, Van Damme P, Mathei C, et al. Safety and
86. immunogenicity of a hepatitis B vaccine formulated with a
87. novel adjuvant system. Vaccine 1998; 16:708.
88. Traquina P, Morandi M, Contorni M, Van Nest G. MF59
89. adjuvant enhances the antibody response to recombinant
90. hepatitis B surface antigen vaccine in primates. J Infect Dis
91. 174:1168.
92. Jacques P, Moens G, Desombere I, et al. The immunogenicity
93. and reactogenicity profile of a candidate hepatitis B vaccine
94. in an adult vaccine non-responder population. Vaccine 2002
95. 3644.
96. Sprengers D, Janssen HLA. Immunomodulatory therapy for
97. chronic hepatitis B virus infection. Fundam Clin Pharmacol
98. 19:17–26
99. Tozun N, Ozdogan OC, Cakaloglu Y, et al. A nationwide
100. prevalance study and risk factors for hepatitis A, B, C and
101. D infections in Turkey. Hepatology Volume 2010; 52
102. (Supplement S1): 697A.
103. Houghton M. Prospects for prophylactic and therapeutic
104. vaccines against the hepatitis C viruses. Immunol Rev 2011
105. 99–108.
106. Frey SE, Houghton M, Coates S, et al. Safety and
107. immunogenicity of HCV E1E2 vaccine adjuvanted with
108. MF59 administered to healthy adults. Vaccine 2010; 28
109. -73.
110. Law LMJ, Landi A, Magee WC, Tyrrell DL, Houghton
111. H. Progress towards a hepatitis C virus vaccine. Emerging
112. Microbes and Infections 2013;2:e79. doi:10.1038/
113. emi.2013.79; published online 20 November 2013